Administration algorithm of erythropoiesis stimulating agents for darbepoetin alfa in hemodialysis patients: a randomized controlled study

Administration algorithm of erythropoiesis stimulating agents for darbepoetin alfa in hemodialysis patients: a randomized controlled study - Administration algorithm of erythropoiesis stimulating agents study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013846

Enrollment

200

Registered

2014-04-30

Start date

2014-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with maintenance hemodialysis

Interventions

Darbepoetin alfa dosing using administration algorithm of erythropoiesis stimulating agents Darbepoetin alfa dosing using standard protocol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with maintenance hemodialysis (2) Patients with renal anemia, who are treated with rHuEPO or iron

Exclusion criteria

Exclusion criteria: (1) Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder (2) Patients who are receiving dialysis modalities other than hemodialysis (3) Patients judged as ineligible for this study by the researcher

Design outcomes

Primary

Measure	Time frame
(1) Hemoglobin and erythropoiesis-related indexes (2) Required dose of darbepoetin alfa (3)Blood chemical examination including iron-related, inflammation, nutrition indexes (4)Hemodynamic parameters	—

Countries

Japan

Contacts

Public ContactTadashi Kuji

Yokodai Central Clinic Director

t.kuji@houshinkai.or.jp045-830-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026